IDL Diagnostics (IDLDX) Stock Overview
A vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IDLDX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
IDL Diagnostics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.36 |
| 52 Week High | SEK 0.65 |
| 52 Week Low | SEK 0.32 |
| Beta | 0.88 |
| 1 Month Change | -8.61% |
| 3 Month Change | -35.07% |
| 1 Year Change | -27.80% |
| 3 Year Change | -39.33% |
| 5 Year Change | -85.20% |
| Change since IPO | -89.06% |
Recent News & Updates
Recent updates
Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?
Apr 20
Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)
Feb 27At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?
Nov 07We Think AroCell (STO:AROC) Can Afford To Drive Business Growth
Aug 10AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans
Apr 18We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely
Jan 03
Shareholder Returns
| IDLDX | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -5.0% | -0.6% | -1.1% |
| 1Y | -27.8% | 23.7% | 3.7% |
Return vs Industry: IDLDX underperformed the Swedish Life Sciences industry which returned 23.6% over the past year.
Return vs Market: IDLDX underperformed the Swedish Market which returned 3.7% over the past year.
Price Volatility
| IDLDX volatility | |
|---|---|
| IDLDX Average Weekly Movement | 9.5% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.9% |
| 10% least volatile stocks in SE Market | 2.9% |
Stable Share Price: IDLDX's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: IDLDX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 20 | Anders Hultman | idldiagnostics.com |
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025.
IDL Diagnostics AB (publ) Fundamentals Summary
| IDLDX fundamental statistics | |
|---|---|
| Market cap | SEK 83.16m |
| Earnings (TTM) | -SEK 46.07m |
| Revenue (TTM) | SEK 54.81m |
Is IDLDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDLDX income statement (TTM) | |
|---|---|
| Revenue | SEK 54.81m |
| Cost of Revenue | SEK 45.69m |
| Gross Profit | SEK 9.13m |
| Other Expenses | SEK 55.20m |
| Earnings | -SEK 46.07m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 12, 2025
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 16.65% |
| Net Profit Margin | -84.06% |
| Debt/Equity Ratio | 0% |
How did IDLDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 10:13 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IDL Diagnostics AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Oscar Bergman | Redeye |